Colossal Biosciences Seeks at Least $20 Billion Valuation

Colossal Biosciences, a startup focused on de-extinction of the woolly mammoth, is seeking a valuation of at least $20 billion in its next funding round. The company now has some revenue, a shift from its pre-revenue status during its last fundraising. The lead investor for this round has not been disclosed. Colossal has previously raised significant capital from high-profile investors, including venture capital firms and celebrities. The company's work involves genetic engineering and synthetic biology to revive extinct species, with potential applications in conservation and biotechnology.

Global Impact

Economically, a $20B valuation for a de-extinction startup would mark a major milestone for the synthetic biology sector, potentially attracting more capital and talent. Technologically, it could accelerate development of gene-editing and cloning techniques with broader applications in medicine and agriculture.